Precision for Medicine and Trialbee Partner to Advance Clinical Trials for Complex Therapies and Speed Shift Toward Precision Medicine
MALMO, SWEDEN & BETHESDA, MD — August 5, 2021 – Clinical research organization Precision for Medicine and Trialbee, a patient matching and enrollment platform, are addressing complexities in clinical development through a new partnership that will accelerate the future of precision medicine. Trialbee’s advanced analytics will play a critical role in matching patients to trials conducted by Precision for Medicine and extending recruitment to a more diverse, targeted patient community for the development of complex, personalized medicine.
On-Demand Webinar: Strategies for Building a Cell Therapy Manufacturing Facility
Building an advanced therapeutic manufacturing facility is complex and highly customized. In this webinar, a panel of industry experts discuss the challenges faced when building a cutting-edge cell therapy manufacturing facility from build-out to operational readiness and share key insights into their company’s approach to mitigating risk under accelerated timelines.
Bigger and Better Together: PRECISIONeffect Acquires Pascāle, Expanding Capabilities with PR and Social Media Services
Boston – August 3, 2021 – PRECISIONeffect, the industry’s only healthcare advertising agency dedicated to changing the standard of care, today announced that it has acquired Pascāle, an international healthcare communications company specializing in public relations and social media. Pascāle has an almost two-decade history of launching full-scale, creative-fueled PR and social media campaigns to drive results for healthcare clients worldwide.
On-Demand Panel: CAR-TCR Summit, 2021
The promise of cell-based immunotherapy is giving hope to patients around the globe living with devastating disease; but the future of the cell therapy industry is still unclear. This panel discussion co-hosted by Precision for Medicine and Precision ADVANCE will feature key insights and discussion from advanced therapy leaders on the pros and cons of developing Autologous and Allogeneic cell therapies.
Employers Have Variety of Approaches for High-Cost Drugs
As more high-cost drugs, including one-time gene therapies, come onto the market, employers are considering implementing a variety of contracting models to make sure their employees have access to these agents. Precision’s Jorge Font and Erin Lopata explore these innovative new approaches, as well as the challenges in executing them.